Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer


QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion

Therapie für nicht-kleinzelliges Lungenkarzinom: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu KRAZATI von Mirati Therapeutics
Therapie für nicht-kleinzelliges Lungenkarzinom: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu KRAZATI von Mirati Therapeutics


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat von der US-amerikanischen Arzneimittelzulassungsbehörde FDA die Zulassung des therascreen® KRAS RGQ PCR-Kits (therascreen KRAS-Kit) als

Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Acadia Healthcare Provides Business Outlook Ahead of Investor Day: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Provides Business Outlook Ahead of Investor Day


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) will host its first Investor Day beginning at approximately 9:00 a.m. Eastern Time today, Wednesday, December 7, 2022, in New York City.



During the

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection


Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles

Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced its newest operating joint venture hospital, Maple Heights Behavioral Health, located in Fort Wayne, Indiana, and held a ribbon-tying

LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place

Convatec Group PLC: Total Voting Rights
Convatec Group PLC: Total Voting Rights
Convatec Group PLC: Total Voting Rights
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Chemed Corporation to Present at the BofA Securities 2022 Virtual Home Care Conference:
Chemed Corporation to Present at the BofA Securities 2022 Virtual Home Care Conference


Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2022 Virtual Home Care Conference on Tuesday, December 5, 2022, at 10:40 AM (ET).



The presentation will

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma


Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). GBM is the most common and one of the most

Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program


Charles River Laboratories International, Inc. (NYSE: CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/



CSL Vifor and Fresenius Kabi today announced that